Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Paller, A. S. [1 ,2 ]
Guttman-Yassky, E. [3 ,4 ]
Boguniewicz, M. [5 ,6 ]
Sun, Y. [7 ]
Wolfe, K. [8 ]
Kroeller-Schoen, S. [9 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA
[3] Mt Sinai Med Ctr, Icahn Sch Med, New York, NY 10029 USA
[4] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA
[5] Natl Jewish Hlth, Denver, CO USA
[6] Univ Colorado, Sch Med, Denver, CO USA
[7] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[8] Sanofi, Bridgewater, NJ USA
[9] Sanofi, Frankfurt, Germany
来源：
ALLERGOLOGIE | 2022年 / 45卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P6.04
引用
收藏
页码：621 / 622
页数：2
相关论文
共 50 条
  • [1] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to &lt; 6 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Dillon, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
  • [2] DUPILUMAB REDUCES BIOMARKERS INDICATIVE OF TYPE 2 INFLAMMATION IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Paller, Amy S.
    Flohr, Carsten
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Wipperman, Matthew F.
    Rodriguez Marco, Ainara
    Wolfe, Kelley
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 30 - 31
  • [3] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to 5 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Levit, N.
    Wolfe, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S250 - S250
  • [4] Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to &lt; 6 YearsWith Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Sun, Yiping
    Wolfe, Kelley
    Dillon, Myles
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 100 - 100
  • [5] DUPILUMAB REDUCES ITCH IN CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AGED 6 MONTHS TO 5 YEARS
    Paller, A. S.
    Siegfried, E. C.
    Yosipovitch, G.
    Kwatra, S. G.
    Praestgaard, A.
    Prescilla, R.
    Wang, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S58
  • [6] Dupilumab Reduces Itch in Children with Moderate-to-Severe Atopic Dermatitis Aged 6 Months to 5 Years
    Paller, Amy S.
    Siegfried, Elaine C.
    Yosipovitch, Gil
    Kwatra, Shawn G.
    Praestgaard, Amy
    Wang, Zhixiao
    Prescilla, Randy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB151 - AB151
  • [7] Dupilumab Reduces Inflammatory Biomarkers in Patients Aged 6 Months to 18 Years With Moderate-to-Severe or Severe Atopic Dermatitis
    Beck, Lisa
    Muraro, Antonella
    Boguniewicz, Mark
    Chen, Zhen
    Levit, Noah
    Marco, Ainara Rodriguez
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB152 - AB152
  • [8] Efficacy and safety of dupilumab in children aged ≥ 6 months to &lt; 6 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Cork, Michael J.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sun, Yiping
    O'Malley, John T.
    Bansal, Ashish
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 12 - 12
  • [9] Efficacy and safety of dupilumab in children aged ≥ 6 months to &lt; 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Simpson, E. L.
    Siegfried, E. C.
    Cork, M. J.
    Wollenberg, A.
    Arkwright, P. D.
    Soong, W.
    Gonzalez, M. E.
    Schneider, L. C.
    Sidbury, R.
    Lockshin, B.
    Wang, Z.
    Mannent, L. P.
    Amin, N.
    Sun, Y.
    Laws, E.
    Akinlade, B.
    Kosloski, M. P.
    Dubost-Brama, A.
    O'Malley, J. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E173 - E173
  • [10] Efficacy and safety of dupilumab in children aged ≥6 months to &lt;6 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sidbury, Robert
    Lockshin, Benjamin
    Xiao, Jing
    O'Malley, John T.
    Bansal, Ashish
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
12345